Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (TWST) is a leader in synthetic DNA production, utilizing a proprietary semiconductor-based platform to drive innovations across biotechnology and healthcare. This page provides investors and industry professionals with timely, accurate updates on TWST's strategic developments and operational milestones.
Access consolidated press releases and news covering earnings announcements, product launches, research breakthroughs, and partnerships. Our curated updates ensure you stay informed about TWST's advancements in gene synthesis, high-throughput manufacturing, and applications in precision medicine.
Key content includes quarterly financial results, regulatory filings, technology patents, and collaborations with academic or industry partners. All materials are sourced directly from verified company communications to maintain factual integrity.
Bookmark this page for streamlined access to TWST's evolving role in synthetic biology. Check regularly for critical updates impacting market positioning and technological leadership in DNA synthesis.
Twist Bioscience (TWST) has launched Twist Multiplexed Gene Fragments (MGFs), pools of directly synthesized double-stranded DNA up to 500 base pairs in length, with no limit on sequence number, enabling high-throughput screening applications. This offering allows for rapid screening of diverse targets for CRISPR and genome engineering, antibody discovery, protein engineering, and more. The customizable fragments have a quick turnaround time, starting at 8 business days, making them versatile for various applications.
Twist Bioscience announced the granting of 87,200 restricted stock units to 26 new employees as inducement for joining the company. The RSUs vest over a 48-month period for each employee, with 25% vesting on the one year anniversary of employment and 1/16 vesting quarterly thereafter.
Twist Bioscience (NASDAQ: TWST) reported a record revenue of $75.3M in the second quarter of fiscal 2024, showing a 25% increase over the same period in fiscal 2023. Orders also grew by 45% to $93.2M. The company increased its revenue guidance for fiscal 2024 to a range of $300M to $304M and its gross margin guidance to 41.5% to 42.0%. Twist Bioscience continues to focus on profitability and aims to improve gross margin to over 50% by the end of fiscal 2025.